O
O
HO
N
N
CN

13
11
18
12
14
1
4
5
7
8
2
6
9
10
19
20
21
24
25
22
26
23
27
16
17
15
28

1
2
3
4
5
6
7
8
9

```
* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 25   CA/CAPLUS - Russian Agency for Patents and Trademarks
                   (ROSPATENT) added to list of core patent offices covered
 NEWS  4  FEB 28   PATDPAFULL - New display fields provide for legal status
                   data from INPADOC
 NEWS  5  FEB 28   BABS - Current-awareness alerts (SDIs) available
 NEWS  6  FEB 28   MEDLINE/LMEDLINE reloaded
 NEWS  7  MAR 02   GBFULL: New full-text patent database on STN
 NEWS  8  MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  9  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  10 MAR 22   KOREAPAT now updated monthly; patent information enhanced
 NEWS  11 MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  12 MAR 22   PATDPASPC - New patent database available
 NEWS  13 MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  14 APR 04   EPFULL enhanced with additional patent information and new
                   fields
 NEWS  15 APR 04   EMBASE - Database reloaded and enhanced
 NEWS  16 APR 18   New CAS Information Use Policies available online
 NEWS  17 APR 25   Patent searching, including current-awareness alerts (SDIs),
                   based on application date in CA/CAplus and USPATFULL/USPAT2
                   may be affected by a change in filing date for U.S.
                   applications.
 NEWS  18 APR 28   Improved searching of U.S. Patent Classifications for
                   U.S. patent records in CA/CAplus

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.42       0.42

FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAY 2005 HIGHEST RN 850130-09-5
DICTIONARY FILE UPDATES: 9 MAY 2005 HIGHEST RN 850130-09-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Page 1-A



Page 1-B



Page 2-A



Page 2-B

NODE ATTRIBUTES:

HCOUNT	IS M1	AT	14
NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS C	AT	11
NSPEC	IS C	AT	12
NSPEC	IS C	AT	13
NSPEC	IS C	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS C	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS R	AT	22
NSPEC	IS R	AT	23
NSPEC	IS R	AT	24
NSPEC	IS R	AT	25

```
NSPEC   IS R      AT  26
NSPEC   IS R      AT  27
NSPEC   IS C      AT  28
NSPEC   IS C      AT  29
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  11 12 13 14 18 28 29
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1  19
NUMBER OF NODES IS  29

STEREO ATTRIBUTES: NONE


=> s l1
SAMPLE SEARCH INITIATED 15:39:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     87 TO ITERATE

100.0% PROCESSED      87 ITERATIONS                              2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1181 TO     2299
PROJECTED ANSWERS:               2 TO      124

L2             2 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 15:39:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1987 TO ITERATE

100.0% PROCESSED    1987 ITERATIONS                             23 ANSWERS
SEARCH TIME: 00.00.01

L3            23 SEA SSS FUL L1

=> s l3 and hamanaka, e?/au
NUMERIC VALUE NOT VALID 'HAMANAKA, E?'
              0 HAMANAKA, E?/AU
L4            0 L3 AND HAMANAKA, E?/AU

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             168.51     168.93

FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 10 May 2005 VOL 142 ISS 20
FILE LAST UPDATED: 9 May 2005 (20050509/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3 and hamanaka, e?/au
            13 L3
            63 HAMANAKA, E?/AU
L5           0 L3 AND HAMANAKA, E?/AU

=> s l3 and angel, g?/au
            13 L3
           107 ANGEL, G?/AU
L6           0 L3 AND ANGEL, G?/AU

=> s l3 and mularski, c?/au
            13 L3
            10 MULARSKI, C?/AU
L7           0 L3 AND MULARSKI, C?/AU

=> s l3 and ruggeri, r?/au
            13 L3
           141 RUGGERI, R?/AU
L8           0 L3 AND RUGGERI, R?/AU

=> s l3 and wester, r?/au
            13 L3
           294 WESTER, R?/AU
L9           0 L3 AND WESTER, R?/AU

=> s l3
L10         13 L3

=> d l10, ibib abs hitstr, 11-13

L10  ANSWER 11 OF 13  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Citing References

ACCESSION NUMBER: 2000:366036 HCAPLUS
DOCUMENT NUMBER: 133:4646
TITLE: Crystal modification A of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S): Himmler, Thomas; Hallenbach, Werner; Rast, Hubert
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19854356	A1	20000531	DE 1998-19854356	19981125
CA 2351712	AA	20000602	CA 1999-2351712	19991115
WO 2000031075	A1	20000602	WO 1999-EP8775	19991115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9915669	A	20010814	BR 1999-15669	19991115
EP 1133496	A1	20010919	EP 1999-958040	19991115
EP 1133496	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101438	T2	20011022	TR 2001-200101438	19991115
JP 2002530406	T2	20020917	JP 2000-583903	19991115
NZ 511861	A	20021220	NZ 1999-511861	19991115
AU 763883	B2	20030731	AU 2000-15533	19991115
CN 1135229	B	20040121	CN 1999-813686	19991115
TW 576835	B	20040221	TW 1999-88119810	19991115
AT 264858	E	20040515	AT 1999-958040	19991115
PT 1133496	T	20040831	PT 1999-958040	19991115
ES 2217843	T3	20041101	ES 1999-958040	19991115
RU 2247122	C2	20050227	RU 2001-117525	19991115
NO 2001002460	A	20010518	NO 2001-2460	20010518
US 6436955	B1	20020820	US 2001-856669	20010523
HK 1042703	A1	20041203	HK 2002-104444	20020613
PRIORITY APPLN. INFO.:			DE 1998-19854356 A	19981125
			WO 1999-EP8775 W	19991115

GI



I

AB The title compd. in crystal modification A (I), useful as a medical and veterinary bactericide, is stable during extended storage without conversion to the amorphous form or any other crystal modification, and is less hygroscopic than the amorphous form of the compd. I is produced by dissolving the amorphous compd. or an unknown modification of it in hot water or a hot water-alc. mixt., adding an alc. (esp. EtOH or iso-PrOH), and cooling to room temp. I (m. 249-252°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.

IT **195532-12-8P**

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(crystal modification A of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:366035 HCAPLUS
DOCUMENT NUMBER: 133:4645
TITLE: Crystal modification B of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S): Himmler, Thomas; Hallenbach, Werner; Rast, Hubert
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19854355	A1	20000531	DE 1998-19854355	19981125
CA 2351707	AA	20000602	CA 1999-2351707	19991115
WO 2000031076	A1	20000602	WO 1999-EP8776	19991115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9915682	A	20010814	BR 1999-15682	19991115
EP 1133497	A1	20010919	EP 1999-959278	19991115
EP 1133497	B1	20050223		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101444	T2	20020121	TR 2001-200101444	19991115
JP 2002530407	T2	20020917	JP 2000-583904	19991115
NZ 511862	A	20030829	NZ 1999-511862	19991115
AU 767890	B2	20031127	AU 2000-16517	19991115

AT 289606	E	20050315	AT 1999-959278		19991115
RU 2248355	C2	20050320	RU 2001-117521		19991115
NO 2001002461	A	20010518	NO 2001-2461		20010518
US 6664268	B1	20031216	US 2001-856670		20010523
HK 1042705	A1	20050311	HK 2002-104458		20020614
PRIORITY APPLN. INFO.:			DE 1998-19854355	A	19981125
			WO 1999-EP8776	W	19991115

OTHER SOURCE(S): CASREACT 133:4645
GI



I

AB The title compd. in crystal modification B (I), useful as a medical and veterinary bactericide, is stable during extended storage without conversion to the amorphous form or any other crystal modification, and is less hygroscopic than the amorphous form of the compd. I is produced either (a) by reaction of 7-halo-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid with (1S,6S)-2,8-diazabicyclo[4.3.0]nonane in the presence of a base in a mixt. of EtOH and a polar aprotic diluent such as N-methylpyrrolidone, DMF, or sulfolane, or (b) by heating an unknown modification of the compd. in the presence of a base in EtOH, n-PrOH, iso-PrOH, or a mixt. of one of these alcs. with one of the polar aprotic diluents named previously. I (m. 243-245°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.

IT **195532-12-8P**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(crystal modification B of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:579724 HCAPLUS

DOCUMENT NUMBER: 127:248093
TITLE: 8-Cyano-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid derivatives
INVENTOR(S): Bartel, Stefan; Jaetsch, Thomas; Himmler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; Stegemann, Michael; Stupp, Hans-Peter; Wetzstein, Heinz-Georg
PATENT ASSIGNEE(S): Bayer A.-G., Germany; Bartel, Stefan; Jaetsch, Thomas; Himmler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; et al.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9731001	A1	19970828	WO 1997-EP637	19970212
W: AU, BB, BG, BR, BY, CA, CN, CZ, HU, IL, JP, KR, KZ, LK, MX, NO, NZ, PL, RO, RU, SK, TR, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19633805	A1	19970828	DE 1996-19633805	19960822
ZA 9701507	A	19970916	ZA 1997-1507	19970202
CA 2247020	AA	19970828	CA 1997-2247020	19970212
AU 9717689	A1	19970910	AU 1997-17689	19970212
AU 715341	B2	20000120		
EP 882049	A1	19981209	EP 1997-903260	19970212
EP 882049	B1	20021120		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
CN 1211984	A	19990324	CN 1997-192523	19970212
CN 1073112	B	20011017		
BR 9707606	A	19990727	BR 1997-7606	19970212
NZ 331468	A	20000228	NZ 1997-331468	19970212
JP 2000504734	T2	20000418	JP 1997-529755	19970212
IL 125444	A1	20010319	IL 1997-125444	19970212
RU 2173318	C2	20010910	RU 1998-117814	19970212
EP 1215202	A1	20020619	EP 2002-6519	19970212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
AT 228130	E	20021215	AT 1997-903260	19970212
CZ 291251	B6	20030115	CZ 1998-2684	19970212
ES 2184060	T3	20030401	ES 1997-903260	19970212
PT 882049	T	20030430	PT 1997-903260	19970212
PL 186737	B1	20040227	PL 1997-328577	19970212
TW 390879	B	20000521	TW 1997-86101994	19970220
US 6323213	B1	20011127	US 1998-125191	19980813
NO 9803819	A	19980820	NO 1998-3819	19980820
NO 311521	B1	20011203		
HK 1018903	A1	20020510	HK 1999-104030	19990917
US 6278013	B1	20010821	US 2000-718062	20001121
CN 1335301	A	20020213	CN 2001-110855	20010228

PRIORITY APPLN. INFO.:

DE 1996-19606762	A	19960223
DE 1996-19633805	A	19960822
EP 1997-903260	A3	19970212
WO 1997-EP637	W	19970212
US 1998-125191	A3	19980813

OTHER SOURCE(S): MARPAT 127:248093

GI



AB Title compds. I [R1 = H, alkyl, optionally substituted by OH, OMe, NH2, NHMe, NMe2, or (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; R2 = H, benzyl, alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, CH=CHCO2R3, CH2CH2CO2R3, CH2CH2CN, CH2CH2COMe, CH2COMe; R3 = Me, Et, R4(NHCHR5CO)n; R4 = H, alkyl, CO2CMe3; R5 = H, alkyl, hydroxyalkyl, aminoalkyl, thioalkyl, carboxyalkyl, benzyl; n = 1, 2; Y = O, S] were prepd. for use as antibacterial agents. Thus, I [R1 = OH, R2 = H, Y = O] was prepd. by aminating the 7-chloroquinoline. I [R1 = OH, R2 = H, Y = O] had min. inhibitory concns. against a no. of bacteria that were superior to those of enrofloxacin.

IT **195532-12-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of diazabicylononylquinolinecarboxylic acid derivs. as bactericides)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



not seen by author

IT **195532-14-0P** **195532-16-2P** **195532-18-4P**
195532-20-8P **195532-22-0P** **195532-25-3P**
195532-27-5P **195532-29-7P** **195532-31-1P**
195532-33-3P **195532-36-6P** **195532-39-9P**
195532-42-4P **195532-45-7P** **195532-48-0P**
195532-58-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diazabicylononylquinolinecarboxylic acid derivs. as bactericides)

RN 195532-14-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-16-2 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8
CMF C21 H21 F N4 O3

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 195532-18-4 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8
CMF C21 H21 F N4 O3

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 195532-20-8 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8
CMF C21 H21 F N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 195532-22-0 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxo-1-propenyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, [4aS-[1(E),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 195532-25-3 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-[(5-methyl-2-oxo-1,3-dioxolan-4-yl)methyl]-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, [4aS-(4aα,7aα)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-27-5 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-(3-oxobutyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-29-7 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-7-[1-(2-cyanoethyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-31-1 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-(2-oxopropyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-33-3 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-36-6 HCAPLUS
CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-39-9 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(S*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-42-4 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-3-methyl-1-oxobutyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-45-7 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxo-3-phenylpropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-48-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-4-methyl-1-oxopentyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-58-2 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monosodium salt, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Na

=> d his

```
      (FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005)

      FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005
L1              STRUCTURE UPLOADED
L2            2 S L1
L3           23 S L1 FULL
L4            0 S L3 AND HAMANAKA, E?/AU

      FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005
L5            0 S L3 AND HAMANAKA, E?/AU
L6            0 S L3 AND ANGEL, G?/AU
L7            0 S L3 AND MULARSKI, C?/AU
L8            0 S L3 AND RUGGERI, R?/AU
L9            0 S L3 AND WESTER, R?/AU
L10          13 S L3

=> d l10, ibib abs hitstr, 1-13

L10  ANSWER 1 OF 13  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Other References

```
ACCESSION NUMBER:         2005:177894  HCAPLUS
DOCUMENT NUMBER:          142:254561
TITLE:                    Use of quinolone antibiotics for controlling bacterial
                          diseases of the oral cavity
INVENTOR(S):              Daube, Gert; Edingloh, Markus; Stephan, Bernd; Pirro,
                          Franz; Limet, Agnes
PATENT ASSIGNEE(S):       Bayer Healthcare AG, Germany
SOURCE:                   PCT Int. Appl., 16 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

      PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
      --------------      ----   --------    --------------------    --------
      WO 2005018641        A2    20050303    WO 2004-EP8629          20040802
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
              TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
              EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
              SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
              SN, TD, TG
      DE 10337191          A1    20050317    DE 2003-10337191        20030813
PRIORITY APPLN. INFO.:                      DE 2003-10337191    A   20030813
AB    The invention relates to the use of certain quinolone antibiotics for
      controlling bacterial diseases of the oral cavity, esp. in veterinary
      medicine.
IT 195532-12-8, Pradofloxacin
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
         (quinolone antibiotic for control of bacterial disease of oral cavity)
RN    195532-12-8  HCAPLUS
```

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:800774 HCAPLUS
DOCUMENT NUMBER: 141:282840
TITLE: Controlled-release drug delivery system containing saccharose acetate isobutyrate (SAIB)
INVENTOR(S): Fraatz, Kristine; Mertin, Dirk; Heep, Iris
PATENT ASSIGNEE(S): Bayer Healthcare AG, Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10312346	A1	20040930	DE 2003-10312346	20030320
WO 2004082658	A1	20040930	WO 2004-EP2318	20040306

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 2003-10312346 A 20030320

AB The invention concerns controlled-release drug delivery systems that include (a) a drug; (b) saccharose acetate isobutyrate (SAIB); (c) glycerinformal, isopropylidene glycerol or their mixt. as solvent. A cosolvent can be added; they are selected from the group of ethanol, n-butanol and benzyl alc. Thus a formulation contained (wt./wt.%): SAIB 40; pradofloxacin 3; n-butanol 3; ethanol 5; 1N HCl 1.7; glycerinformal to 100.

IT **195532-12-8**, Pradofloxacin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled release drug delivery system contg. saccharose acetate isobutyrate (SAIB))

RN 195532-12-8 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:971863 HCAPLUS
DOCUMENT NUMBER: 140:31484
TITLE: Pharmaceutical preparations, especially quinolone antibiotics, for oral administration, containing ion-exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents
INVENTOR(S): Mertin, Dirk; Edingloh, Markus; Daube, Gert
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany; Bayer Healthcare AG
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101422	A2	20031211	WO 2003-EP5228	20030519
WO 2003101422	A3	20041209		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10224086	A1	20031211	DE 2002-10224086	20020531
BR 2003011511	A	20050222	BR 2003-11511	20030519
EP 1513500	A2	20050316	EP 2003-755931	20030519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: DE 2002-10224086 A 20020531
WO 2003-EP5228 W 20030519

AB The invention relates to pharmaceutical prepns. for oral administration, said prepns. contg. at least one active ingredient which is bound to an

ion exchanger. The inventive prepns. also contain an intrinsically viscous gelling agent as a thickening agent in order to improve their phys. stability and acceptance, esp. by animals. Thus 0.18 kg methyl-p-hydroxybenzoate and 0.02 kg propyl-p-hydroxybenzoate were dissolved in 75.0 kg hot water; 0.3 kg Xanthan gum and 0.3 kg bentonite were added under vigorous mixing; mixing was continued for one hour at 70°C. The mixt. was cooled; 6.0 kg pradofloxacin, 18.0 kG Amberlite IRP 64 and 1.0 kg vanillin were added to the sol.

IT **195532-12-8**, Pradofloxacin
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical prepns., esp. quinolone antibiotics, for oral administration, contg. ion-exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | More References

ACCESSION NUMBER: 2003:744337 HCAPLUS
DOCUMENT NUMBER: 139:301379
TITLE: Clinical efficacy and safety of pradofloxacin in the treatment of canine pyoderma and wound infections under field conditions
AUTHOR(S): Stephan, B.; Hellmann, K.; Liege, P.; Granier, S.; Knoppe, T. N.; Heinen, E.; Greife, H. A.
CORPORATE SOURCE: Animal Health Business Group, Bayer AG, Leverkusen, Germany
SOURCE: Journal of Veterinary Pharmacology and Therapeutics (2003), 26(Suppl. 1), 217-218
CODEN: JVPTD9; ISSN: 0140-7783
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Pradofloxacin is a novel 8-cyanofluoroquinolone with improved in vitro activity against a wide range of pathogenic bacteria. Tablets of different strengths are currently developed for the treatment of bacterial infections in dogs and cats. The objective of this work was to assess the clin. efficacy and safety of pradofloxacin in the treatment of canine pyoderma and wound infections.

IT **195532-12-8**, Pradofloxacin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological

activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(clin. efficacy and safety of pradofloxacin in treatment of canine pyoderma and wound infections under field conditions)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:744304 HCAPLUS
DOCUMENT NUMBER: 140:331682
TITLE: Analytical method for the determination of pradofloxacin in serum and urine by turbulent flow chromatography/tandem mass spectrometry
AUTHOR(S): Krebber, R.
CORPORATE SOURCE: Bayer CropScience AG, BCS-D-ROCS, Monheim, Germany
SOURCE: Journal of Veterinary Pharmacology and Therapeutics (2003), 26(Suppl. 1), 102-103
CODEN: JVPTD9; ISSN: 0140-7783
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A high-throughput anal. method was developed and validated for the detn. of pradofloxacin (PRA) concns. in body fluids. A turbulent flow chromatog. system 2300 HTLC with auto injector CTC HTS PAL coupled to a tandem mass spectrometer Sciex API 365 was used. Serum and urine samples of dogs and cats were analyzed within a mean accuracy between -1 and 4% and a precision between 5.1 and 7.8%. The method enables direct anal. of PRA in several body fluids. It combines a min. of sample prepn. with fast and highly selective detn. within an extremely wide range of linearity and is therefore highly suitable to assess PRA concns. in pharmacokinetic studies.

IT **195532-12-8**, Pradofloxacin
RL: ANT (Analyte); ANST (Analytical study)
(anal. method for detn. of pradofloxacin in serum and urine by turbulent flow chromatog./tandem mass spectrometry in cats and dogs)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:744303 HCAPLUS
DOCUMENT NUMBER: 140:331734
TITLE: Protein binding of pradofloxacin, a novel 8-cyanofluoroquinolone, in dog and cat plasma
AUTHOR(S): Bregante, M. A.; De Jong, A.; Calvo, A.; Hernandez, E.; Rey, R.; Garcia, M. A.
CORPORATE SOURCE: Veterinary Faculty of University of Zaragoza, Zaragoza, Spain
SOURCE: Journal of Veterinary Pharmacology and Therapeutics (2003), 26(Suppl. 1), 87-88
CODEN: JVPTD9; ISSN: 0140-7783
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The in vitro protein binding of pradofloxacin (PRA) in plasma of dogs and cats was investigated. Enrofloxacin (ENR), the first veterinary fluoroquinolone, was tested as a ref. drug. For concns. of 0.15, 0.75 and 1.50 μg/mL, the percentages of free unbound drug in dog plasma were 63.4±14.8, 63.6±10.5 and 64.2±8.8 for PRA and 59.7±13.3, 54.3±7.3 and 68.4±5.0 for ENR, resp. In cat plasma, the percentages unbound drug were 68.6±7.8, 70.4±11.5, and 71.2±6.2 for PRA and 63.7±10.5, 66.0±9.8 and 73.4±12.5 for ENR. The plasma protein binding of PRA amounted to 29-37% over a ten-fold concn. range: similar findings for ENR (27-46% bound) are in agreement with previous results. A concn. dependency was absent for PRA, but in case of ENR there were statistically significant differences both in dogs and cats; the numerical differences, however, were small.

IT **195532-12-8**, Pradofloxacin
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(protein binding of pradofloxacin, novel 8-cyanofluoroquinolone, in dog and cat plasma)

RN 195532-12-8 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:76654 HCAPLUS
DOCUMENT NUMBER: 138:126984
TITLE: Pharmaceutical preparations for oral administration containing ion exchange resins loaded with active ingredients
INVENTOR(S): Mertin, Dirk; Block, Wolfgang; Hamann, Hans-juergen
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007995	A2	20030130	WO 2002-EP7417	20020704
WO 2003007995	A3	20030731		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10134719	A1	20030206	DE 2001-10134719	20010717
CA 2453616	AA	20030130	CA 2002-2453616	20020704
EP 1411894	A2	20040428	EP 2002-743262	20020704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011149	A	20040629	BR 2002-11149	20020704
JP 2005500332	T2	20050106	JP 2003-513600	20020704
US 2004247560	A1	20041209	US 2004-483635	20040721

PRIORITY APPLN. INFO.:

DE 2001-10134719	A	20010717
WO 2002-EP7417	W	20020704

AB The invention relates to pharmaceutical prepns. contg. at least one active ingredient which is linked to an ion exchanger. In order to improve the palatability and to increase the stability, at least 90 % of said active ingredient/ion exchanger particles are smaller than 50 μm. Quinolone antibiotics are bound to cation exchange resins, esp. for the prepn. cat medication. Thus 3.86 kg enrofloxacin and 19.24 kg Amberlite IRP64 were

suspended in 76.90 kg purified water and stirred for at least 8 h at room temp. The suspension was transferred to a filter dryer, filtered and dried at 85°C. The obtained 17.96 kg of enrofloxacin-loaded resin was suspended with 60 g colloidal silica, 100.30 kg neutral oil (e.g. Miglyol 812) and ground in a perl mill; at least 90% of the particles were smaller than 10 μm.

IT **195532-12-8**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical prepns. for oral administration contg. ion exchange resins loaded with active ingredients)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:607382 HCAPLUS
DOCUMENT NUMBER: 133:213147
TITLE: Crystal modification C of 8-cyano-1-cyclopropyl-7-[(1S,6S)-2,8-diazabicyclo[4.3.0]nonan-8-yl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S): Rast, Hubert; Himmler, Thomas
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19908449	A1	20000831	DE 1999-19908449	19990226
CA 2362801	AA	20000908	CA 2000-2362801	20000214
WO 2000052009	A1	20000908	WO 2000-EP1202	20000214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
NZ 513750	A	20010928	NZ 2000-513750	20000214

EP 1155018	A1	20011121	EP 2000-909166	20000214
EP 1155018	B1	20021030		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008493	A	20020205	BR 2000-8493	20000214
TR 200102434	T2	20020321	TR 2001-200102434	20000214
JP 2002538158	T2	20021112	JP 2000-602235	20000214
AT 226952	E	20021115	AT 2000-909166	20000214
PT 1155018	T	20030228	PT 2000-909166	20000214
ES 2181644	T3	20030301	ES 2000-909166	20000214
AU 763003	B2	20030710	AU 2000-31543	20000214
RU 2248356	C2	20050320	RU 2001-126300	20000214
ZA 2001006289	A	20020731	ZA 2001-6289	20010731
NO 2001004061	A	20010821	NO 2001-4061	20010821
US 6649762	B1	20031118	US 2001-914090	20010822
PRIORITY APPLN. INFO.:			DE 1999-19908449	A 19990226
			WO 2000-EP1202	W 20000214

GI



I

AB The title compd. (I) is converted to stable crystal modification C (m. 235-237°) by holding I at room temp. and relative humidity ≥92% until no further wt. gain occurs, drying, and heating to above the conversion temp. (150-180°). I modification D is characterized by its powder x-ray diffractogram, IR spectrum, and by DTA. I is highly active against pathogenic bacteria in human and veterinary medicine.

IT **195532-12-8**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystal modification D of cyanocyclopropyl(diazabicyclononanyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:607381 HCAPLUS
DOCUMENT NUMBER: 133:213146
TITLE: Crystal modification D of 8-cyano-1-cyclopropyl-7-[(1S,6S)-2,8-diazabicyclo[4.3.0]nonan-8-yl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S): Himmler, Thomas; Rast, Hubert
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19908448	A1	20000831	DE 1999-19908448	19990226
CA 2362804	AA	20000908	CA 2000-2362804	20000214
WO 2000052010	A1	20000908	WO 2000-EP1203	20000214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1159277	A1	20011205	EP 2000-909167	20000214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008520	A	20011218	BR 2000-8520	20000214
TR 200102435	T2	20020121	TR 2001-200102435	20000214
JP 2002538159	T2	20021112	JP 2000-602236	20000214
AU 760710	B2	20030522	AU 2000-31544	20000214
AU 2000031544	A5	20000921		
NZ 513749	A	20031031	NZ 2000-513749	20000214
RU 2248357	C2	20050320	RU 2001-126301	20000214
ZA 2001006050	A	20020724	ZA 2001-6050	20010724
NO 2001004059	A	20010821	NO 2001-4059	20010821
US 6492391	B1	20021210	US 2001-914031	20010822

PRIORITY APPLN. INFO.:

DE 1999-19908448	A	19990226
WO 2000-EP1203	W	20000214

GI



I

AB The title compd. (I) is converted to stable crystal modification D (m. 261-265°) by dissolving I in H2O to a concn. of 1-3 wt.%, allowing the soln. to stand until a ppt. forms, removing the ppt. by filtration,

drying the remaining soln., and heating the solid obtained to above the transition temp. (130-160°). I modification D is characterized by its powder x-ray diffractogram, IR spectrum, and by DTA. I is highly active against pathogenic bacteria in human and veterinary medicine.

IT **195532-12-8**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(crystal modification D of cyanocyclopropyl(diazabicyclononanyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full-Text | Citing References

ACCESSION NUMBER:	2000:366037 HCAPLUS
DOCUMENT NUMBER:	133:4647
TITLE:	Semihydrochloride of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S):	Himmler, Thomas; Rast, Hubert
PATENT ASSIGNEE(S):	Bayer A.-G., Germany
SOURCE:	Ger. Offen., 16 pp. CODEN: GWXXBX
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19854357	A1	20000531	DE 1998-19854357	19981125
CA 2351714	AA	20000602	CA 1999-2351714	19991115
WO 2000031077	A1	20000602	WO 1999-EP8778	19991115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9915684	A	20010814	BR 1999-15684	19991115

EP 1133495	A1	20010919	EP 1999-955995	19991115
EP 1133495	B1	20021009		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101443	T2	20010921	TR 2001-200101443	19991115
JP 2002530408	T2	20020917	JP 2000-583905	19991115
AT 225790	E	20021015	AT 1999-955995	19991115
ES 2181488	T3	20030216	ES 1999-955995	19991115
PT 1133495	T	20030228	PT 1999-955995	19991115
AU 759769	B2	20030501	AU 2000-12716	19991115
NZ 511863	A	20030530	NZ 1999-511863	19991115
RU 2242475	C2	20041220	RU 2001-117528	19991115
NO 2001002532	A	20010702	NO 2001-2532	20010523
PRIORITY APPLN. INFO.:			DE 1998-19854357 A	19981125
			WO 1999-EP8778 W	19991115

OTHER SOURCE(S): CASREACT 133:4647
GI



AB The title compd. (I), useful as a medical and veterinary bactericide, shows good water soly. (19 wt.%). I is produced by reaction of 7-halo-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid with (1S,6S)-2,8-diazabicyclo[4.3.0]nonane in the presence of a base in one of the following diluents: (a) a C≥4 aliph. alc., (b) a mixt. of a C>3 alc. with the polar aprotic diluent, N-methylpyrrolidone; (c) a mixt. of n-PrOH with DMF. I (m. 278-280°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.

IT **271252-05-2P**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(semihydrochloride of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 271252-05-2 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (2:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:366036 HCAPLUS
DOCUMENT NUMBER: 133:4646
TITLE: Crystal modification A of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S): Himmler, Thomas; Hallenbach, Werner; Rast, Hubert
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19854356	A1	20000531	DE 1998-19854356	19981125
CA 2351712	AA	20000602	CA 1999-2351712	19991115
WO 2000031075	A1	20000602	WO 1999-EP8775	19991115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9915669	A	20010814	BR 1999-15669	19991115
EP 1133496	A1	20010919	EP 1999-958040	19991115
EP 1133496	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101438	T2	20011022	TR 2001-200101438	19991115
JP 2002530406	T2	20020917	JP 2000-583903	19991115
NZ 511861	A	20021220	NZ 1999-511861	19991115
AU 763883	B2	20030731	AU 2000-15533	19991115
CN 1135229	B	20040121	CN 1999-813686	19991115
TW 576835	B	20040221	TW 1999-88119810	19991115
AT 264858	E	20040515	AT 1999-958040	19991115
PT 1133496	T	20040831	PT 1999-958040	19991115
ES 2217843	T3	20041101	ES 1999-958040	19991115
RU 2247122	C2	20050227	RU 2001-117525	19991115

NO 2001002460	A	20010518	NO 2001-2460		20010518
US 6436955	B1	20020820	US 2001-856669		20010523
HK 1042703	A1	20041203	HK 2002-104444		20020613
PRIORITY APPLN. INFO.:			DE 1998-19854356	A	19981125
			WO 1999-EP8775	W	19991115

GI



AB The title compd. in crystal modification A (I), useful as a medical and veterinary bactericide, is stable during extended storage without conversion to the amorphous form or any other crystal modification, and is less hygroscopic than the amorphous form of the compd. I is produced by dissolving the amorphous compd. or an unknown modification of it in hot water or a hot water-alc. mixt., adding an alc. (esp. EtOH or iso-PrOH), and cooling to room temp. I (m. 249-252°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.

IT **195532-12-8P**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(crystal modification A of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER:	2000:366035 HCAPLUS
DOCUMENT NUMBER:	133:4645
TITLE:	Crystal modification B of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S):	Himmler, Thomas; Hallenbach, Werner; Rast, Hubert
PATENT ASSIGNEE(S):	Bayer A.-G., Germany
SOURCE:	Ger. Offen., 8 pp.
	CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19854355	A1	20000531	DE 1998-19854355	19981125
CA 2351707	AA	20000602	CA 1999-2351707	19991115
WO 2000031076	A1	20000602	WO 1999-EP8776	19991115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9915682	A	20010814	BR 1999-15682	19991115
EP 1133497	A1	20010919	EP 1999-959278	19991115
EP 1133497	B1	20050223		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101444	T2	20020121	TR 2001-200101444	19991115
JP 2002530407	T2	20020917	JP 2000-583904	19991115
NZ 511862	A	20030829	NZ 1999-511862	19991115
AU 767890	B2	20031127	AU 2000-16517	19991115
AT 289606	E	20050315	AT 1999-959278	19991115
RU 2248355	C2	20050320	RU 2001-117521	19991115
NO 2001002461	A	20010518	NO 2001-2461	20010518
US 6664268	B1	20031216	US 2001-856670	20010523
HK 1042705	A1	20050311	HK 2002-104458	20020614

PRIORITY APPLN. INFO.: DE 1998-19854355 A 19981125
WO 1999-EP8776 W 19991115

OTHER SOURCE(S): CASREACT 133:4645
GI



I

AB The title compd. in crystal modification B (I), useful as a medical and veterinary bactericide, is stable during extended storage without conversion to the amorphous form or any other crystal modification, and is less hygroscopic than the amorphous form of the compd. I is produced either (a) by reaction of 7-halo-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid with (1S,6S)-2,8-diazabicyclo[4.3.0]nonane in the presence of a base in a mixt. of EtOH and a polar aprotic diluent such as N-methylpyrrolidone, DMF, or sulfolane, or (b) by heating an unknown modification of the compd. in the presence of a base in EtOH, n-PrOH, iso-PrOH, or a mixt. of one of these alcs. with one of the polar aprotic diluents named previously. I (m. 243-245°) is characterized by its powder x-ray diffractogram, differential thermogram,

and IR spectrum.

IT **195532-12-8P**

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(crystal modification B of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Other References

ACCESSION NUMBER: 1997:579724 HCAPLUS
DOCUMENT NUMBER: 127:248093
TITLE: 8-Cyano-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid derivatives
INVENTOR(S): Bartel, Stefan; Jaetsch, Thomas; Himmler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; Stegemann, Michael; Stupp, Hans-Peter; Wetzstein, Heinz-Georg
PATENT ASSIGNEE(S): Bayer A.-G., Germany; Bartel, Stefan; Jaetsch, Thomas; Himmler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; et al.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9731001	A1	19970828	WO 1997-EP637	19970212
W: AU, BB, BG, BR, BY, CA, CN, CZ, HU, IL, JP, KR, KZ, LK, MX, NO, NZ, PL, RO, RU, SK, TR, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19633805	A1	19970828	DE 1996-19633805	19960822
ZA 9701507	A	19970916	ZA 1997-1507	19970202
CA 2247020	AA	19970828	CA 1997-2247020	19970212
AU 9717689	A1	19970910	AU 1997-17689	19970212
AU 715341	B2	20000120		
EP 882049	A1	19981209	EP 1997-903260	19970212
EP 882049	B1	20021120		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI						
CN 1211984	A	19990324	CN 1997-192523			19970212
CN 1073112	B	20011017				
BR 9707606	A	19990727	BR 1997-7606			19970212
NZ 331468	A	20000228	NZ 1997-331468			19970212
JP 2000504734	T2	20000418	JP 1997-529755			19970212
IL 125444	A1	20010319	IL 1997-125444			19970212
RU 2173318	C2	20010910	RU 1998-117814			19970212
EP 1215202	A1	20020619	EP 2002-6519			19970212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI						
AT 228130	E	20021215	AT 1997-903260			19970212
CZ 291251	B6	20030115	CZ 1998-2684			19970212
ES 2184060	T3	20030401	ES 1997-903260			19970212
PT 882049	T	20030430	PT 1997-903260			19970212
PL 186737	B1	20040227	PL 1997-328577			19970212
TW 390879	B	20000521	TW 1997-86101994			19970220
US 6323213	B1	20011127	US 1998-125191			19980813
NO 9803819	A	19980820	NO 1998-3819			19980820
NO 311521	B1	20011203				
HK 1018903	A1	20020510	HK 1999-104030			19990917
US 6278013	B1	20010821	US 2000-718062			20001121
CN 1335301	A	20020213	CN 2001-110855			20010228
PRIORITY APPLN. INFO.:			DE 1996-19606762	A		19960223
			DE 1996-19633805	A		19960822
			EP 1997-903260	A3		19970212
			WO 1997-EP637	W		19970212
			US 1998-125191	A3		19980813

OTHER SOURCE(S): MARPAT 127:248093

GI



I

AB Title compds. I [R1 = H, alkyl, optionally substituted by OH, OMe, NH2, NHMe, NMe2, or (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; R2 = H, benzyl, alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, CH=CHCO2R3, CH2CH2CO2R3, CH2CH2CN, CH2CH2COMe, CH2COMe; R3 = Me, Et, R4(NHCHR5CO)n; R4 = H, alkyl, CO2CMe3; R5 = H, alkyl, hydroxyalkyl, aminoalkyl, thioalkyl, carboxyalkyl, benzyl; n = 1, 2; Y = O, S] were prepd. for use as antibacterial agents. Thus, I [R1 = OH, R2 = H, Y = O] was prepd. by aminating the 7-chloroquinoline. I [R1 = OH, R2 = H, Y = O] had min. inhibitory concns. against a no. of bacteria that were superior to those of enrofloxacin.

IT **195532-12-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of diazabicylononylquinolinecarboxylic acid derivs. as bactericides)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 195532-14-0P 195532-16-2P 195532-18-4P
195532-20-8P 195532-22-0P 195532-25-3P
195532-27-5P 195532-29-7P 195532-31-1P
195532-33-3P 195532-36-6P 195532-39-9P
195532-42-4P 195532-45-7P 195532-48-0P
195532-58-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diazabicylononylquinolinecarboxylic acid derivs. as bactericides)

RN 195532-14-0 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-16-2 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8
CMF C21 H21 F N4 O3

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 195532-18-4 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8
CMF C21 H21 F N4 O3

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 195532-20-8 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8
CMF C21 H21 F N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 195532-22-0 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxo-1-propenyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, [4aS-[1(E),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 195532-25-3 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-[(5-methyl-2-oxo-1,3-dioxolan-4-yl)methyl]-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, [4aS-(4aα,7aα)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-27-5 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-(3-oxobutyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-29-7 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-7-[1-(2-cyanoethyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-31-1 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-(2-oxopropyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-33-3 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-36-6 HCAPLUS
CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-39-9 HCAPLUS
CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(S*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-42-4 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-3-methyl-1-oxobutyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-45-7 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxo-3-phenylpropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-48-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-4-methyl-1-oxopentyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-58-2 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monosodium salt, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




```
=> s hamanaka, e?/au
L11          63 HAMANAKA, E?/AU

=> s hamanaka, e?/au
L12          63 HAMANAKA, E?/AU

=> s guzman-perez, a?/au
L13          18 GUZMAN-PEREZ, A?/AU

=> s mularski, c?/au
L14          10 MULARSKI, C?/AU

=> s ruggeri, r?/au
L15         141 RUGGERI, R?/AU

=> s wester, r?/au
L16         294 WESTER, R?/AU

=> s l11 and l13 and l14 and l15 and l16
L17           2 L11 AND L13 AND L14 AND L15 AND L16

=> d l17, ibib abs, 1-2
```

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:207067 HCAPLUS
DOCUMENT NUMBER: 135:40413
TITLE: Discovery of zoniporide: A potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility
AUTHOR(S): **Guzman-Perez, A.**; **Wester, R. T.**; Allen, M. C.; Brown, J. A.; Buchholz, A. R.; Cook, E. R.; Day, W. W.; **Hamanaka, E. S.**; Kennedy, S. P.; Knight, D. R.; Kowalczyk, P. J.; Marala, R. B.; **Mularski, C. J.**; Novomisle, W. A.; **Ruggeri, R. B.**; Tracey, W. R.; Hill, R. J.
CORPORATE SOURCE: Pfizer Global Research and Development, Pfizer Inc., Groton, CT, 06340, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(6), 803-807
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Zoniporide (CP-597,396) is a potent and selective inhibitor of NHE-1, which exhibits high aq. soly. and acceptable pharmacokinetics for i.v. administration. The discovery, synthesis, activities, and rat and dog pharmacokinetics of this compd. are presented. The potency and selectivity of zoniporide may be due to the conformation that the mol. adopts due to the presence of a cyclopropyl and a 5-quinolinyl substituent on the central pyrazole ring of the mol.
REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:566034 HCAPLUS
DOCUMENT NUMBER: 131:199699
TITLE: N-[(Substituted five-membered di- or triaza diunsaturated ring)carbonyl]guanidine derivatives for the treatment of ischemia
INVENTOR(S): **Hamanaka, Ernest S.**; **Guzman-Perez, Angel**; **Ruggeri, Roger B.**; **Wester, Ronald T.**; **Mularski, Christian J.**
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 246 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943663	A1	19990902	WO 1999-IB206	19990205

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,

TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2321642	AA	19990902	CA 1999-2321642	19990205
AU 9920706	A1	19990915	AU 1999-20706	19990205
AU 739403	B2	20011011		
BR 9908332	A	20001107	BR 1999-8332	19990205
EP 1056729	A1	20001206	EP 1999-901083	19990205
EP 1056729	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
TR 200002480	T2	20001221	TR 2000-200002480	19990205
JP 2002504546	T2	20020212	JP 2000-533420	19990205
EP 1454902	A1	20040908	EP 2004-8203	19990205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 286034	E	20050115	AT 1999-901083	19990205
ZA 9901578	A	20000828	ZA 1999-1578	19990226
US 6492401	B1	20021210	US 1999-367731	19990818
NO 2000004192	A	20000822	NO 2000-4192	20000822
HR 2000000550	A1	20010228	HR 2000-550	20000824
BG 104803	A	20010531	BG 2000-104803	20000927
HR 2001000666	A1	20011031	HR 2001-666	20010829
US 2003149043	A1	20030807	US 2002-315369	20021209
JP 2005041879	A2	20050217	JP 2004-248129	20040827

PRIORITY APPLN. INFO.:	US 1998-76362P	P 19980227
	EP 1999-901083	A3 19990205
	JP 2000-533420	A3 19990205
	WO 1999-IB206	W 19990205
	US 1999-367731	A3 19990818

OTHER SOURCE(S): MARPAT 131:199699
GI



II

AB Guanidine derivs. ZCON:C(NH2)2 [I; Z = certain (un)substituted, diunsatd., diazoles and triazoles] and their pharmaceutically acceptable salts and/or prodrugs are disclosed, for use as inhibitors of sodium-hydrogen exchanger type 1 (NHE-1). Also disclosed are methods of using I, and pharmaceutical compns. contg. them. I are useful for the redn. of tissue damage resulting from tissue ischemia (no data). A large no. of compds. I and their intermediates were prepd. and/or specifically claimed. For instance, guanidine-HCl was converted to the free base, taken up in THF-DMF mixt., and coupled with 5-methyl-2-(2-methoxyphenyl)-2H-1,2,3-triazole-4-carboxylic acid (pre-activated with carbonyldiimidazole), and the resultant guanidine deriv. was isolated and acidified with HCl in MeOH, to give title compd. II.HCl in 17% yield.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

```
     (FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005)

     FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005
L1             STRUCTURE UPLOADED
L2               2 S L1
L3              23 S L1 FULL
L4               0 S L3 AND HAMANAKA, E?/AU

     FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005
L5               0 S L3 AND HAMANAKA, E?/AU
L6               0 S L3 AND ANGEL, G?/AU
L7               0 S L3 AND MULARSKI, C?/AU
L8               0 S L3 AND RUGGERI, R?/AU
L9               0 S L3 AND WESTER, R?/AU
L10             13 S L3
L11             63 S HAMANAKA, E?/AU
L12             63 S HAMANAKA, E?/AU
L13             18 S GUZMAN-PEREZ, A?/AU
L14             10 S MULARSKI, C?/AU
L15            141 S RUGGERI, R?/AU
L16            294 S WESTER, R?/AU
L17              2 S L11 AND L13 AND L14 AND L15 AND L16

=> file caold
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                113.74     282.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -13.14     -13.14

FILE 'CAOLD' ENTERED AT 15:47:53 ON 10 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> d his

     (FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005)

     FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005
L1             STRUCTURE UPLOADED
```

```
L2             2 S L1
L3            23 S L1 FULL
L4             0 S L3 AND HAMANAKA, E?/AU

     FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005
L5             0 S L3 AND HAMANAKA, E?/AU
L6             0 S L3 AND ANGEL, G?/AU
L7             0 S L3 AND MULARSKI, C?/AU
L8             0 S L3 AND RUGGERI, R?/AU
L9             0 S L3 AND WESTER, R?/AU
L10           13 S L3
L11           63 S HAMANAKA, E?/AU
L12           63 S HAMANAKA, E?/AU
L13           18 S GUZMAN-PEREZ, A?/AU
L14           10 S MULARSKI, C?/AU
L15          141 S RUGGERI, R?/AU
L16          294 S WESTER, R?/AU
L17            2 S L11 AND L13 AND L14 AND L15 AND L16

     FILE 'CAOLD' ENTERED AT 15:47:53 ON 10 MAY 2005

=> s l3
L18            0 L3

=> file reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 3.87     286.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00     -13.14

FILE 'REGISTRY' ENTERED AT 15:53:01 ON 10 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    9 MAY 2005  HIGHEST RN 850130-09-5
DICTIONARY FILE UPDATES:   9 MAY 2005  HIGHEST RN 850130-09-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************
*                                                           *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                           *
*************************************************************
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L19 STRUCTURE UPLOADED

=> d l19
L19 HAS NO ANSWERS
L19 STR



NODE ATTRIBUTES:
HCOUNT IS M1 AT 8
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS R AT 6
NSPEC IS R AT 7
NSPEC IS R AT 8
NSPEC IS R AT 9
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE

=> s l19
SAMPLE SEARCH INITIATED 15:54:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8004 TO ITERATE

12.5% PROCESSED 1000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 154718 TO 165442
PROJECTED ANSWERS: 1 TO 329

L20 1 SEA SSS SAM L19

```
=> s l20 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 15:54:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 160147 TO ITERATE

100.0% PROCESSED  160147 ITERATIONS                          198 ANSWERS
SEARCH TIME: 00.00.01

L21         198 SEA SSS FUL L19

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   162.19     448.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -13.14

FILE 'HCAPLUS' ENTERED AT 15:54:56 ON 10 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 10 May 2005  VOL 142 ISS 20
FILE LAST UPDATED: 9 May 2005  (20050509/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005)

     FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005
L1             STRUCTURE UPLOADED
L2           2 S L1
L3          23 S L1 FULL
L4           0 S L3 AND HAMANAKA, E?/AU

     FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005
L5           0 S L3 AND HAMANAKA, E?/AU
L6           0 S L3 AND ANGEL, G?/AU
L7           0 S L3 AND MULARSKI, C?/AU
L8           0 S L3 AND RUGGERI, R?/AU
```

```
L9            0 S L3 AND WESTER, R?/AU
L10          13 S L3
L11          63 S HAMANAKA, E?/AU
L12          63 S HAMANAKA, E?/AU
L13          18 S GUZMAN-PEREZ, A?/AU
L14          10 S MULARSKI, C?/AU
L15         141 S RUGGERI, R?/AU
L16         294 S WESTER, R?/AU
L17           2 S L11 AND L13 AND L14 AND L15 AND L16

     FILE 'CAOLD' ENTERED AT 15:47:53 ON 10 MAY 2005
L18           0 S L3

     FILE 'REGISTRY' ENTERED AT 15:53:01 ON 10 MAY 2005
L19             STRUCTURE UPLOADED
L20           1 S L19
L21         198 S L20 FULL

     FILE 'HCAPLUS' ENTERED AT 15:54:56 ON 10 MAY 2005

=> s l21/rct
           197 L21
       2729491 RCT/RL
L22        118 L21/RCT
                (L21 (L) RCT/RL)

=> s l3/prep
            13 L3
       3300320 PREP/RL
L23          4 L3/PREP
                (L3 (L) PREP/RL)

=> s l23 and l22
L24          3 L23 AND L22

=> d l24, ibib abs hitstr, 1-3

L24  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Cited References

```
ACCESSION NUMBER:         2000:366037  HCAPLUS
DOCUMENT NUMBER:          133:4647
TITLE:                    Semihydrochloride of 8-cyano-1-cyclopropyl-7-(1S,6S-
                          2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-
                          dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S):              Himmler, Thomas; Rast, Hubert
PATENT ASSIGNEE(S):       Bayer A.-G., Germany
SOURCE:                   Ger. Offen., 16 pp.
                          CODEN: GWXXBX
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     DE 19854357           A1    20000531    DE 1998-19854357        19981125
     CA 2351714            AA    20000602    CA 1999-2351714         19991115
     WO 2000031077         A1    20000602    WO 1999-EP8778          19991115
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
```

CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 9915684	A	20010814	BR 1999-15684		19991115
EP 1133495	A1	20010919	EP 1999-955995		19991115
EP 1133495	B1	20021009			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200101443	T2	20010921	TR 2001-200101443		19991115
JP 2002530408	T2	20020917	JP 2000-583905		19991115
AT 225790	E	20021015	AT 1999-955995		19991115
ES 2181488	T3	20030216	ES 1999-955995		19991115
PT 1133495	T	20030228	PT 1999-955995		19991115
AU 759769	B2	20030501	AU 2000-12716		19991115
NZ 511863	A	20030530	NZ 1999-511863		19991115
RU 2242475	C2	20041220	RU 2001-117528		19991115
NO 2001002532	A	20010702	NO 2001-2532		20010523
PRIORITY APPLN. INFO.:			DE 1998-19854357	A	19981125
			WO 1999-EP8778	W	19991115

OTHER SOURCE(S): CASREACT 133:4647
GI



I

AB The title compd. (I), useful as a medical and veterinary bactericide, shows good water soly. (19 wt.%). I is produced by reaction of 7-halo-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid with (1S,6S)-2,8-diazabicyclo[4.3.0]nonane in the presence of a base in one of the following diluents: (a) a C≥4 aliph. alc., (b) a mixt. of a C>3 alc. with the polar aprotic diluent, N-methylpyrrolidone; (c) a mixt. of n-PrOH with DMF. I (m. 278-280°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.

IT **271252-05-2P**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); **PREP (Preparation)**; PROC (Process)
(semihydrochloride of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)
RN 271252-05-2 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride (2:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 151213-40-0
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(semihydrochloride of cyanocyclopropyl(diazabicyclononyl)fluorodihydroo
xoquinolinecarboxylic acid)
RN 151213-40-0 HCAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L24 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:366035 HCAPLUS
DOCUMENT NUMBER: 133:4645
TITLE: Crystal modification B of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
INVENTOR(S): Himmler, Thomas; Hallenbach, Werner; Rast, Hubert
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19854355	A1	20000531	DE 1998-19854355	19981125
CA 2351707	AA	20000602	CA 1999-2351707	19991115
WO 2000031076	A1	20000602	WO 1999-EP8776	19991115

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 9915682	A	20010814	BR 1999-15682		19991115
EP 1133497	A1	20010919	EP 1999-959278		19991115
EP 1133497	B1	20050223			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200101444	T2	20020121	TR 2001-200101444		19991115
JP 2002530407	T2	20020917	JP 2000-583904		19991115
NZ 511862	A	20030829	NZ 1999-511862		19991115
AU 767890	B2	20031127	AU 2000-16517		19991115
AT 289606	E	20050315	AT 1999-959278		19991115
RU 2248355	C2	20050320	RU 2001-117521		19991115
NO 2001002461	A	20010518	NO 2001-2461		20010518
US 6664268	B1	20031216	US 2001-856670		20010523
HK 1042705	A1	20050311	HK 2002-104458		20020614
PRIORITY APPLN. INFO.:			DE 1998-19854355	A	19981125
			WO 1999-EP8776	W	19991115

OTHER SOURCE(S): CASREACT 133:4645
GI



I

AB The title compd. in crystal modification B (I), useful as a medical and veterinary bactericide, is stable during extended storage without conversion to the amorphous form or any other crystal modification, and is less hygroscopic than the amorphous form of the compd. I is produced either (a) by reaction of 7-halo-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid with (1S,6S)-2,8-diazabicyclo[4.3.0]nonane in the presence of a base in a mixt. of EtOH and a polar aprotic diluent such as N-methylpyrrolidone, DMF, or sulfolane, or (b) by heating an unknown modification of the compd. in the presence of a base in EtOH, n-PrOH, iso-PrOH, or a mixt. of one of these alcs. with one of the polar aprotic diluents named previously. I (m. 243-245°) is characterized by its powder x-ray diffractogram, differential thermogram, and IR spectrum.

IT **195532-12-8P**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); **PREP (Preparation)**; PROC (Process)
(crystal modification B of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 151213-40-0
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(crystal modification B of cyanocyclopropyl(diazabicyclononyl)fluorodihydrooxoquinolinecarboxylic acid)
RN 151213-40-0 HCAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L24 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | More References

ACCESSION NUMBER: 1997:579724 HCAPLUS
DOCUMENT NUMBER: 127:248093
TITLE: 8-Cyano-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid derivatives
INVENTOR(S): Bartel, Stefan; Jaetsch, Thomas; Himmler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; Stegemann, Michael; Stupp, Hans-Peter; Wetzstein, Heinz-Georg
PATENT ASSIGNEE(S): Bayer A.-G., Germany; Bartel, Stefan; Jaetsch, Thomas; Himmler, Thomas; Rast, Hans-Georg; Hallenbach, Werner; Heinen, Ernst; Pirro, Franz; Scheer, Martin; et al.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9731001	A1	19970828	WO 1997-EP637	19970212
W: AU, BB, BG, BR, BY, CA, CN, CZ, HU, IL, JP, KR, KZ, LK, MX, NO, NZ, PL, RO, RU, SK, TR, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19633805	A1	19970828	DE 1996-19633805	19960822
ZA 9701507	A	19970916	ZA 1997-1507	19970202
CA 2247020	AA	19970828	CA 1997-2247020	19970212
AU 9717689	A1	19970910	AU 1997-17689	19970212
AU 715341	B2	20000120		

EP 882049	A1	19981209	EP 1997-903260	19970212
EP 882049	B1	20021120		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
CN 1211984	A	19990324	CN 1997-192523	19970212
CN 1073112	B	20011017		
BR 9707606	A	19990727	BR 1997-7606	19970212
NZ 331468	A	20000228	NZ 1997-331468	19970212
JP 2000504734	T2	20000418	JP 1997-529755	19970212
IL 125444	A1	20010319	IL 1997-125444	19970212
RU 2173318	C2	20010910	RU 1998-117814	19970212
EP 1215202	A1	20020619	EP 2002-6519	19970212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
AT 228130	E	20021215	AT 1997-903260	19970212
CZ 291251	B6	20030115	CZ 1998-2684	19970212
ES 2184060	T3	20030401	ES 1997-903260	19970212
PT 882049	T	20030430	PT 1997-903260	19970212
PL 186737	B1	20040227	PL 1997-328577	19970212
TW 390879	B	20000521	TW 1997-86101994	19970220
US 6323213	B1	20011127	US 1998-125191	19980813
NO 9803819	A	19980820	NO 1998-3819	19980820
NO 311521	B1	20011203		
HK 1018903	A1	20020510	HK 1999-104030	19990917
US 6278013	B1	20010821	US 2000-718062	20001121
CN 1335301	A	20020213	CN 2001-110855	20010228

PRIORITY APPLN. INFO.:

DE 1996-19606762	A	19960223
DE 1996-19633805	A	19960822
EP 1997-903260	A3	19970212
WO 1997-EP637	W	19970212
US 1998-125191	A3	19980813

OTHER SOURCE(S): MARPAT 127:248093

GI



I

AB Title compds. I [R1 = H, alkyl, optionally substituted by OH, OMe, NH2, NHMe, NMe2, or (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; R2 = H, benzyl, alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, CH=CHCO2R3, CH2CH2CO2R3, CH2CH2CN, CH2CH2COMe, CH2COMe; R3 = Me, Et, R4(NHCHR5CO)n; R4 = H, alkyl, CO2CMe3; R5 = H, alkyl, hydroxyalkyl, aminoalkyl, thioalkyl, carboxyalkyl, benzyl; n = 1, 2; Y = O, S] were prepd. for use as antibacterial agents. Thus, I [R1 = OH, R2 = H, Y = O] was prepd. by aminating the 7-chloroquinoline. I [R1 = OH, R2 = H, Y = O] had min. inhibitory concns. against a no. of bacteria that were superior to those of enrofloxacin.

IT **195532-12-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(prepn. of diazabicylononylquinolinecarboxylic acid derivs. as bactericides)

RN 195532-12-8 HCAPLUS

CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-

[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 151213-40-0
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(prepn. of diazabicylononylquinolinecarboxylic acid derivs. as bactericides)
RN 151213-40-0 HCAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **195532-14-0P** **195532-16-2P** **195532-18-4P**
195532-20-8P **195532-22-0P** **195532-25-3P**
195532-27-5P **195532-29-7P** **195532-31-1P**
195532-33-3P **195532-36-6P** **195532-39-9P**
195532-42-4P **195532-45-7P** **195532-48-0P**
195532-58-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of diazabicylononylquinolinecarboxylic acid derivs. as bactericides)
RN 195532-14-0 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-16-2 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8
CMF C21 H21 F N4 O3

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 195532-18-4 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8
CMF C21 H21 F N4 O3

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 195532-20-8 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 195532-12-8
CMF C21 H21 F N4 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 195532-22-0 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxo-1-propenyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, [4aS-[1(E),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 195532-25-3 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-

[octahydro-1-[(5-methyl-2-oxo-1,3-dioxolan-4-yl)methyl]-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, [4aS-(4aα,7aα)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-27-5 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-(3-oxobutyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-29-7 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-7-[1-(2-cyanoethyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-31-1 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[octahydro-1-(2-oxopropyl)-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-33-3 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-7-[1-(3-ethoxy-3-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-36-6 HCAPLUS
CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-39-9 HCAPLUS
CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxopropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(S*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-42-4 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-3-methyl-1-oxobutyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-45-7 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-1-oxo-3-phenylpropyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 195532-48-0 HCAPLUS

CN 3-Quinolinecarboxylic acid, 7-[1-(2-amino-4-methyl-1-oxopentyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, [4aS-[1(R*),4aα,7aα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195532-58-2 HCAPLUS
CN 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monosodium salt, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 15:35:29 ON 10 MAY 2005)

FILE 'REGISTRY' ENTERED AT 15:36:23 ON 10 MAY 2005
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 23 S L1 FULL
L4 0 S L3 AND HAMANAKA, E?/AU

FILE 'HCAPLUS' ENTERED AT 15:40:40 ON 10 MAY 2005
L5 0 S L3 AND HAMANAKA, E?/AU
L6 0 S L3 AND ANGEL, G?/AU
L7 0 S L3 AND MULARSKI, C?/AU
L8 0 S L3 AND RUGGERI, R?/AU
L9 0 S L3 AND WESTER, R?/AU
L10 13 S L3
L11 63 S HAMANAKA, E?/AU
L12 63 S HAMANAKA, E?/AU
L13 18 S GUZMAN-PEREZ, A?/AU
L14 10 S MULARSKI, C?/AU
L15 141 S RUGGERI, R?/AU

```
L16          294 S WESTER, R?/AU
L17            2 S L11 AND L13 AND L14 AND L15 AND L16

     FILE 'CAOLD' ENTERED AT 15:47:53 ON 10 MAY 2005
L18            0 S L3

     FILE 'REGISTRY' ENTERED AT 15:53:01 ON 10 MAY 2005
L19              STRUCTURE UPLOADED
L20            1 S L19
L21          198 S L20 FULL

     FILE 'HCAPLUS' ENTERED AT 15:54:56 ON 10 MAY 2005
L22          118 S L21/RCT
L23            4 S L3/PREP
L24            3 S L23 AND L22

=>
```